...
首页> 外文期刊>Journal of pharmaceutical sciences. >Evaluation of the pharmacokinetics of All-Trans-Retinoic Acid (ATRA) in wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines.
【24h】

Evaluation of the pharmacokinetics of All-Trans-Retinoic Acid (ATRA) in wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines.

机译:静脉注射装于三丁酸甘油酯微乳中的ATRA后,对wistar大鼠全反式维甲酸(ATRA)的药代动力学及其对caco-2和HepG2细胞系的细胞活性的评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The pharmacokinetics of all-trans-retinoic acid (ATRA), an anti-cancer drug was highly variable due to its poor aqueous solubility. In this study, we investigated the pharmacokinetics of ATRA in male Wistar rats following intravenous administration of the ATRA loaded tributyrin emulsion. In vitro, the ATRA emulsion was proved binding to apolipoprotein(s). In vivo, the clearance of ATRA was significantly reduced by formulating into the tributyrin emulsion, leading to higher AUCs. Co-administration with 17alpha-ethynylestradiol, a compound known to upregulate the activity of low-density lipoprotein receptors in tissues, significantly increased the K(e), V, and CL of ATRA. The variation of plasma AUCs after administering the ATRA emulsion to the healthy rats was two times less than that after the ATRA solution. The IC(50) in ATRA of the ATRA emulsion for the Caco-2 carcinoma cells was 3.8 microg/mL lower than 6 microg/mL of the ATRA solution. The IC(50) of the emulsion for the HepG2 carcinoma cells was 2.8 microg/mL, while IC(50) was not achieved with the ATRA solution over the test concentration range. The finding indicated that the tributyrin emulsion could be used as a carrier for ATRA and enhances the drug effect by reducing the clearance and increasing the in vitro activity. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:2844-2853, 2008.
机译:全反式维甲酸(ATRA)是一种抗癌药物,其水溶性差,因此其药代动力学变化很大。在这项研究中,我们调查了ATRA加载的三丁酸酯乳剂静脉内给药后在雄性Wistar大鼠中ATRA的药代动力学。在体外,证明ATRA乳剂与载脂蛋白结合。在体内,通过配制成三丁酸甘油酯乳液可显着降低ATRA的清除率,从而导致较高的AUC。与17alpha-乙炔基雌二醇(一种已知会上调组织中低密度脂蛋白受体活性的化合物)的共同给药显着增加了ATRA的K(e),V和CL。给予健康大鼠ATRA乳剂后血浆AUC的变化比ATRA溶液后血浆AUC的变化小两倍。用于Caco-2癌细胞的ATRA乳剂的ATRA中的IC(50)比ATRA溶液的6 microg / mL低3.8微克/毫升。用于HepG2癌细胞的乳液的IC(50)为2.8微克/毫升,而在测试浓度范围内,用ATRA溶液未达到IC(50)。该发现表明,三丁酸甘油酯乳剂可以用作ATRA的载体,并通过减少清除率和增加体外活性来增强药物作用。 (c)2007 Wiley-Liss,Inc.和美国药剂师协会J Pharm Sci 97:2844-2853,2008。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号